LIVN News and Press, LivaNova PLC From 08/02/21

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also intends to grant the underwriters of the offering a 30-day option to acquire up to an a...

Image source: The Motley Fool. LivaNova PLC (NASDAQ: LIVN) Q2 2021 Earnings Call Jul 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: LivaNova PLC (LIVN) Q2 2021 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2021 Earnings Conference Call July 28, 2021, 8:00 am ET Company Participants Matthew Dodds - SVP, Corporate Development Damien McDonald - CEO Alex Shvartsburg - Interim CFO Lindsey Little - Senior Director, IR Conference Call Participants Rick Wise - Stifel Mike Matson ...

The following slide deck was published by LivaNova PLC in conjunction with their 2021 Q2 earnings call. For further details see: LivaNova PLC 2021 Q2 - Results - Earnings Call Presentation

LivaNova (LIVN) has appointed Alex Shvartsburg to the position of chief financial officer effective August 01.Shvartsburg, who served as the interim CFO since October 31, adds 25 years of relevant industry experience to the role, the company said, announcing its Q2 2021 results today.In ...

LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021. For the second quarter of 2021, worldwide sales from continuing operations were $264.5 million, an increase of 45.2 percent on a repor...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second quarter 20...

Harris Associates’ 13F portfolio value increased from $51.71B to $58.52B this quarter. They increased Humana, General Dynamics and Regeneron Pharmaceuticals, while decreasing Agilent Technologies, Mastercard, TE Connectivity and CNH Industrial. The top three positions are A...

LivaNova (LIVN) announces that the U.S. FDA has given the go-ahead for the company's clinical study to evaluate its aura6000 system to treat obstructive sleep apnea.With the approval, LivaNova will immediately launch the OSPREY clinical study to demonstrate the safety and effectiveness of the...

Company to launch OSPREY investigational device exemption clinical study in the U.S. LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to proceed w...